camizestrant may be superior to fulvestrant in patients with hr-positive, her2-negative bc
Published 1 year ago • 116 plays • Length 4:05Download video MP4
Download video MP3
Similar videos
-
0:22
quimioterapia en cct100
-
1:39
quimioterapia contra el cáncer de mama
-
5:57
phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer patients
-
13:08
her2 positive breast cancer: everything you must know
-
3:02
trial investigates multiparametric prognostic score in early hr /her2- breast cancer
-
5:50
her2climb: investigating tucatinib with capecitabine and trastuzumab in her2-positive metastatic...
-
4:26
independent validation of the her2dx genomic test in her2-positive breast cancer
-
4:42
t-dm1 may extend pfs among patients with unresectable locally advanced or metastatic her2-positi...
-
1:31
erbb2 amplifications across sex, race, and cancer types studied to guide her2 therapies
-
4:19
abemaciclib plus nsai for hr , her2- advanced breast cancer - monarch 3 interim data
-
5:58
endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in hr and he...
-
3:18
¿necesita la quimioterapia? (do you need chemotherapy?)
-
5:26
trastuzumab deruxtecan shows benefit in patients with her2 mbc
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
1:46
comment: monarch 3 trial: abemaciclib for advanced breast cancer
-
5:42
updates on managing her2-positive early breast cancer
-
4:03
trastuzumab deruxtecan significantly improves pfs in breast cancer patients previously treated w...
-
3:36
datopotamab deruxtecan extends pfs vs chemo for hr /her2- breast cancer
-
1:31
current treatment options for patients with her2-positive metastatic breast cancer